Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients with Cancer

Next Previous
Trial Profile

A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients with Cancer

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 27 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMXT 1501 (Primary) ; Eflornithine (Primary)
  • Indications Advanced breast cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Glioma; Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Sponsors Aminex Therapeutics

Most Recent Events

  • 24 Dec 2024 Status changed from active, no longer recruiting to discontinued.
  • 19 Sep 2024 Status changed from suspended to active, no longer recruiting.
  • 21 Aug 2024 Status changed from recruiting to suspended, after evaluation of safety data.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top